LEGN

Huang Ying

Known title: Chief Executive OfficerCIK: 0001967360

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 11, 2026

Legend Biotech Faces Revised Valuation After CARVYKTI Data. Legend Biotech’s valuation is under review after the release of five‑year CARVYKTI data. JP Morgan and RBC Capital both lowered their price targets to $33 and $56 respectively, signaling a more cautious outlook. The stock is near its 52‑week low and currently tests support at $18.75, adding pressure to the revised targets.

this person other insiders at LEGN

Transaction History

LEGN▼ Sell$0
LEGN▼ Sell$82K
LEGN▼ Sell$87K

We use analytics to understand how market-wall is used. No personal data is sold.